The platform, known as EXO-101, was developed by biotechnology company Exotarget and uses engineered exosomes to deliver genetic instructions to immune cells in vivo. Rather than extracting and modifying T cells externally before reinfusion, the approach aims to programme immune cells within the patient’s body. 

According to the company, the technology is intended to overcome several limitations associated with conventional CAR-T therapy, including manufacturing complexity, treatment delays and reduced efficacy in solid tumours. The platform is designed to selectively target immune cells and induce expression of chimeric antigen receptors capable of recognising tumour-associated targets. 

Preclinical data presented by the company reportedly demonstrated tumour suppression in animal models, alongside generation of functional CAR-T-like immune responses. Exosomes were selected as the delivery vehicle due to their natural role in intercellular communication and their potential to transport biological cargo with lower immunogenicity than some viral delivery systems. 

The announcement reflects growing interest in exosome engineering and cell-free delivery systems within regenerative medicine, oncology and translational biotechnology.

However, the platform remains at a preclinical stage, and further research is needed.